Major Depressive Disorder (MDD) is a prevalent, disabling, and chronic condition. Identifying patients who have not responded to a course of adequate treatment is important as these patients may benefit from adjunctive pharmacotherapy or psychotherapy.
Recommended on NP Psych Navigator
NP Spotlight: Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN
A career as a psychiatric nurse practitioner can be replete with challenges and opportunities. The NP Psych Navigator Spotlight is your chance to learn more about nurse practitioners who are working to advance the profession and mental health in general. In this installment of this series, we profile Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN.
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study
Major depressive disorder (MDD) is a chronic and disabling condition that affects up to 12% of men and 25% of women. MDD is recurrent, with many patients not achieving complete recovery between depressive episodes. The aim of treatment for MDD is remission, which is associated with improved functioning and prognosis.
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial
Major depressive disorder (MDD) is a chronic condition that affects millions of Americans. Unfortunately, first-line monotherapy does not adequately address depressive symptoms for some MDD patients. The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial set out to determine the relative effectiveness and safety of 3 next-step treatments for MDD in patients who failed to respond adequately to at least 1 antidepressant treatment trial of adequate dose and duration. This clinical article summary shares the key findings of this landmark trial.